Drug Profile


Alternative Names: XZP-3287

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jilin Sihuan Pharmaceutical; XuanZhu Pharma
  • Class Antineoplastics
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain cancer; Breast cancer; Solid tumours

Most Recent Events

  • 24 Aug 2017 Birociclib has patent protection in China
  • 12 Jul 2017 The China FDA approves IND application for birociclib in Brain and Brest cancer
  • 01 Nov 2016 Preclinical trials in Solid tumours in China (unspecified route) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top